Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082150 | 1.00 | FFAR1 (0.58) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL14220704 | 1.00 | FFAR1 (0.58) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL3184089 | 0.95 | FFAR1 (0.53) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL29141469 | 0.84 | KMT2A (0.44) | FFAR1ADORA3ADORA2AADORA1MKNK1 | |
| SCHEMBL1584946 | 0.83 | FFAR1 (0.43) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL21135457 | 0.83 | FFAR1 (0.58) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL78460 | 0.83 | FFAR1 (0.43) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL21135481 | 0.83 | FFAR1 (0.58) | FFAR1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL21136648 | 0.83 | FFAR1 (0.46) | FFAR1PPARGMKNK1MKNK2CCNE2 | |
| SCHEMBL21135743 | 0.83 | FFAR1 (0.46) | FFAR1PPARGMKNK1MKNK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180298030-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | Université de Montréal (CA) | 2018-10-18 | — | — | US | disclosed |
| EP-3371196-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | Université de Montréal (CA) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017066863-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017066863-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2017-04-27 | — | — | WO | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | FFAR1 1161/4885ADORA3 43/4885ADORA2A 575/4885 |
| US-20180298030-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | F12, F2, F3 | FFAR1 1161/4885ADORA3 43/4885ADORA2A 575/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | FFAR1 2906/4885ADORA3 991/4885ADORA2A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.